ER

Eric Rose

Mesoblast Limited | Non-Executive Director
Dr Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he checked development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). He is the member of the Clinical Committee Member.

Company and Role

Company
Title
Tenure
Since
MSB
MSB
Mesoblast Limited
  • Non-Executive Director
13yrs, 6mthApr 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
MSB
MSB
Mesoblast Limited
30/06/266,749,274N/A6,413,451N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
MSB
MSB
Mesoblast Limited
18/03/26
Issued
820,000$2.090$1,713,800Issue of options
MSB
MSB
Mesoblast Limited
09/01/26
Buy
1,280,651$0.010$12,807Exercise of options
MSB
MSB
Mesoblast Limited
09/01/26
Exercise
1,280,651$0.010$12,807Exercise of options
MSB
MSB
Mesoblast Limited
09/01/26
Sell
638,670$2.966$1,894,152On-market trade
MSB
MSB
Mesoblast Limited
08/10/25
Sell
120,000$2.940$352,800On-market trade